Epithelix is a Swiss biotech company and the organiser of LIVe2026. For 20 years, Epithelix has been developing ready-to-use primary human airway tissues, including nasal, bronchial, small-airway, and alveolar models — with immunocompetent variants. Their MucilAir™, SmallAir™, and AlveolAir™ tissue systems are reference models in the field, used globally for drug efficacy testing, inhalation toxicology, and respiratory infection research. Epithelix also provides CRO services for a broad range of respiratory applications.